ClinicalTrials.gg
CompletedNCT03859219Updated Sep 16, 2021

A Study to Evaluate Safety and Tolerability of Single Ascending Doses of Rozanolixizumab Administered by Subcutaneous Infusion in Healthy Japanese, Chinese and Caucasian Study Participants

A Phase 1 interventional study of Rozanolixizumab and Placebo in Healthy-volunteers, sponsored by UCB Biopharma S.P.R.L.. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-09-16.

Sponsored by UCB Biopharma S.P.R.L. (part of UCB S.A.) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of the study is to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of rozanolixizumab in japanese, chinese and caucasian healthy-volunteer study participants.

02

Conditions studied

  • Healthy-volunteers

Keywords

  • Rozanolixizumab
  • Caucasian healthy-volunteers
  • Japanese healthy-volunteers
  • Phase 1
  • UCB7665
  • Chinese healthy-volunteers
03

In context

Lead sponsor

UCB Biopharma S.P.R.L. is the lead sponsor of 48 studies on the registry; none are open to participants now.

Of its 15 completed or terminated interventional studies of FDA-regulated products, 12 (80%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Study participant must be 18 to 65 years of age, inclusive, at the time of signing the form (ICF)
  • Study participants who are overtly healthy in the opinion of the investigator as determined by medical history and a general clinical examination, including physical examination, laboratory tests, and cardiac monitoring
  • Study participant must be considered reliable and capable of adhering to the protocol, according to the judgment of the investigator, and is able to communicate satisfactorily with the investigator and comply with all clinical study requirements
  • Japanese or Chinese study participant is of Japanese or Chinese descent, determined by verbal confirmation of familial heritage with all 4 grandparents of Japanese or Chinese descent
  • Caucasian study participant is of Caucasian descent as evidenced in appearance and verbal confirmation of familial heritage with all 4 grandparents of Caucasian descent
  • Study participant is of normal weight as determined by a (BMI) between 18 and 32 kg/m2, inclusive, with a body weight of at least 50 kg (male) or 45 kg (female) and no greater than 100 kg

Exclusion criteria

Exclusion Criteria:

  • Any medical (acute or chronic illness) or psychiatric condition that, in the opinion of the investigator, could harm the study participant or would compromise the study participant's ability to participate in this study.
  • History of known inflammatory bowel disease, active diverticular disease, or a history of confirmed duodenal, gastric, or esophageal ulceration in the previous 6 months
  • Significant allergies to humanized monoclonal antibodies
  • Known to any components of the medicinal product (IMP)
  • multiple or severe drug allergies, intolerance to topical , or severe posttreatment hypersensitivity reactions (including, but not limited to, erythema multiforme major, linear immunoglobulin A [IgA] dermatosis, toxic epidermal necrolysis, and exfoliative dermatitis)
  • Current or chronic history of liver disease, or known hepatic or biliary abnormalities
  • Study participant is splenectomized, or has a clinically relevant active infection (eg, sepsis, pneumonia, abscess) or has had a serious infection (resulting in hospitalization or requiring parenteral antibiotic treatment) within 6 weeks prior to study treatment
  • Treatment with biologic agents (such as monoclonal antibodies including marketed drugs) within 3 months or 5 half-lives (whichever is longer) prior to dosing
  • Received a vaccination within 8 weeks prior to Day -1; or intends to have a vaccination during the course of the study. Prior/Concurrent clinical study experience
  • Exposure to more than 3 new chemical entities within 12 months prior to dosing
  • Previously participated in this clinical study or has previously been assigned to treatment in a clinical study of IMP under investigation in this clinical study
  • Participated in another study of an IMP (or a medical device) within the previous 90 days or 5 half-lives prior to Day -1 (whichever is longer) or is currently participating in another study of an IMP (or a medical device)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    Dose 1 of rozanolixizumab in Japanese subjects

    Japanese subjects will be randomized to receive a predefined dosage of rozanolixizumab in order to maintain the blinding.

    Drug: Rozanolixizumab

  • Experimental
    Dose 2 of rozanolixizumab in Japanese subjects

    Japanese subjects will be randomized to receive a predefined dosage of rozanolixizumab in order to maintain the blinding.

    Drug: Rozanolixizumab

  • Experimental
    Dose 3 of rozanolixizumab in Japanese subjects

    Japanese subjects will be randomized to receive a predefined dosage of rozanolixizumab in order to maintain the blinding.

    Drug: Rozanolixizumab

  • Experimental
    Dose 1 of rozanolixizumab in Caucasian subjects

    Caucasian subjects will be randomized to receive a predefined dosage of rozanolixizumab in order to maintain the blinding.

    Drug: Rozanolixizumab

  • Experimental
    Dose 2 of rozanolixizumab in Caucasian subjects

    Caucasian subjects will be randomized to receive a predefined dosage of rozanolixizumab in order to maintain the blinding.

    Drug: Rozanolixizumab

  • Experimental
    Dose 3 of rozanolixizumab in Caucasian subjects

    Caucasian subjects will be randomized to receive a predefined dosage of rozanolixizumab in order to maintain the blinding.

    Drug: Rozanolixizumab

  • Experimental
    Dose 2 of rozanolixizumab in Chinese subjects

    Chinese subjects will be randomized to receive a predefined dosage of rozanolixizumab in order to maintain the blinding.

    Drug: Rozanolixizumab

  • Experimental
    Dose 3 of rozanolixizumab in Chinese subjects

    Chinese subjects will be randomized to receive a predefined dosage of rozanolixizumab in order to maintain the blinding.

    Drug: Rozanolixizumab

  • Placebo comparator
    Placebo in Japanese subjects

    Japanese subjects will be randomized to receive a predefined dosage of placebo in order to maintain the blinding.

    Drug: Placebo

  • Placebo comparator
    Placebo in Chinese subjects

    Chinese subjects will be randomized to receive a predefined dosage of placebo in order to maintain the blinding.

    Drug: Placebo

  • Placebo comparator
    Placebo in Caucasian subjects

    Caucasian subjects will be randomized to receive a predefined dosage of placebo in order to maintain the blinding.

    Drug: Placebo

Interventions

  • * Pharmaceutical form: solution for injection * Route of administration: subcutaneous infusion

  • DrugPlacebo

    * Pharmaceutical form: solution for injection * Route of administration: subcutaneous infusion

06

What researchers measure

Primary outcomes

  1. Treatment-emergent adverse events (TEAEs) from Baseline to Safety Follow-up (SFU) in healthy Japanese study participants

    An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

    Time frame: From Baseline until Safety Follow-up (up to Week 8)

  2. Treatment-emergent adverse events (TEAEs) from Baseline to Safety Follow-up (SFU) in healthy Chinese study participants

    An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

    Time frame: From Baseline until Safety Follow-up (up to Week 8)

  3. Maximum observed plasma concentration (Cmax) of rozanolixizumab in healthy Japanese study participants

    Maximum observed plasma concentration (Cmax)

    Time frame: Sampling time points for plasma Pharmacokinetics will be as follows: predose, immediately after the end of infusion, 4, 6, 8, 12, 24, 36, 48, 72, 96, 144 and 216 hours

  4. Maximum observed plasma concentration (Cmax) of rozanolixizumab in healthy Chinese study participants

    Maximum observed plasma concentration (Cmax)

    Time frame: Sampling time points for plasma Pharmacokinetics will be as follows: predose, immediately after the end of infusion, 4, 6, 8, 12, 24, 36, 48, 72, 96, 144 and 216 hours

  5. Time to maximum observed plasma concentration (tmax) of rozanolixizumab in healthy Japanese study participants

    Time of observed Cmax (tmax)

    Time frame: Sampling time points for plasma Pharmacokinetics will be as follows: predose, immediately after the end of infusion, 4, 6, 8, 12, 24, 36, 48, 72, 96, 144 and 216 hours

  6. Time to maximum observed plasma concentration (tmax) of rozanolixizumab in healthy Chinese study participants

    Time of observed Cmax (tmax)

    Time frame: Sampling time points for plasma Pharmacokinetics will be as follows: predose, immediately after the end of infusion, 4, 6, 8, 12, 24, 36, 48, 72, 96, 144 and 216 hours

  7. Area under the concentration-time curve from time 0 to time t (AUC(0-t)) of rozanolixizumab in healthy Japanese study participants

    AUC(0-t): Area under the curve from time 0 to time t, the time of last quantifiable concentration

    Time frame: Sampling time points for plasma Pharmacokinetics will be as follows: predose, immediately after the end of infusion, 4, 6, 8, 12, 24, 36, 48, 72, 96, 144 and 216 hours

  8. Area under the concentration-time curve from time 0 to time t (AUC(0-t)) of rozanolixizumab in healthy Chinese study participants

    AUC(0-t): Area under the curve from time 0 to time t, the time of last quantifiable concentration

    Time frame: Sampling time points for plasma Pharmacokinetics will be as follows: predose, immediately after the end of infusion, 4, 6, 8, 12, 24, 36, 48, 72, 96, 144 and 216 hours

Secondary outcomes

  1. Treatment-emergent adverse events (TEAEs) from Baseline to Safety Follow-up (SFU) in healthy Caucasian

    An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

    Time frame: From Baseline until Safety Follow-up (up to Week 8)

  2. AUC(0-t)/BW: Body weight normalized AUC(0-t) of rozanolixizumab

    AUC(0-t)/BW: Body weight normalized AUC(0-t) of rozanolixizumab in healthy Japanese, Chinese and Caucasian study participants

    Time frame: Sampling time points for plasma Pharmacokinetics will be as follows: predose, immediately after the end of infusion, 4, 6, 8, 12, 24, 36, 48, 72, 96, 144 and 216 hours

  3. AUC(0-t)/D: Dose normalized AUC(0-t)

    AUC(0-t)/D: Dose normalized AUC(0-t) of rozanolixizumab in healthy Japanese, Chinese and Caucasian study participants

    Time frame: Sampling time points for plasma Pharmacokinetics will be as follows: predose, immediately after the end of infusion, 4, 6, 8, 12, 24, 36, 48, 72, 96, 144 and 216 hours

  4. AUC(0-t)/D/BW: Dose and body weight normalized AUC(0-t)

    AUC(0-t)/D/BW: Dose and body weight normalized AUC(0-t) of rozanolixizumab in healthy Japanese, Chinese and Caucasian study participants

    Time frame: Sampling time points for plasma Pharmacokinetics will be as follows: predose, immediately after the end of infusion, 4, 6, 8, 12, 24, 36, 48, 72, 96, 144 and 216 hours

  5. Cmax/BW: Body weight normalized Cmax of rozanolixizumab

    Cmax/BW: Body weight normalized Cmax of rozanolixizumab in healthy Japanese, Chinese and Caucasian study participants

    Time frame: Sampling time points for plasma Pharmacokinetics will be as follows: predose, immediately after the end of infusion, 4, 6, 8, 12, 24, 36, 48, 72, 96, 144 and 216 hours

  6. Cmax/D: Dose normalized Cmax

    Cmax/D: Dose normalized Cmax of rozanolixizumab in healthy Japanese, Chinese and Caucasian study participants

    Time frame: Sampling time points for plasma Pharmacokinetics will be as follows: predose, immediately after the end of infusion, 4, 6, 8, 12, 24, 36, 48, 72, 96, 144 and 216 hours

  7. Cmax/D/BW: Dose and body weight normalized Cmax

    Cmax/D/BW: Dose and body weight normalized Cmax of rozanolixizumab in healthy Japanese, Chinese and Caucasian study participants

    Time frame: Sampling time points for plasma Pharmacokinetics will be as follows: predose, immediately after the end of infusion, 4, 6, 8, 12, 24, 36, 48, 72, 96, 144 and 216 hours

07

Study locations

1 site
  • UP0060 1
    London, United Kingdom
08

References and documents

Individual participant data

Plan to share: No — Due to the small sample size in this trial, IPD cannot be adequately anonymized i.e., there is a reasonable likelihood that individual participants could be re-identified. For this reason, data from this trial will not be shared.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2019 to primary completion in Apr 2020, 13 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2019
First posted
Mar 1, 2019
StartActual
Mar 18, 2019
Primary completionActual
Apr 28, 2020
CompletionActual
Apr 28, 2020
Last update
Sep 16, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03859219
Responsible party
Sponsor
First posted
Mar 1, 2019
Start date
Mar 18, 2019
Primary completion
Apr 28, 2020
Completion
Apr 28, 2020
Last update
Sep 16, 2021

Study contacts

UCB Cares
study director · 001 844 599 2273 (UCB)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rozanolixizumab

Start the discussion